<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02830477</url>
  </required_header>
  <id_info>
    <org_study_id>18559</org_study_id>
    <secondary_id>KV1601</secondary_id>
    <nct_id>NCT02830477</nct_id>
  </id_info>
  <brief_title>Study Evaluating &quot;Real World&quot; Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis</brief_title>
  <acronym>TAURUS</acronym>
  <official_title>A Multinational Phase IV Study Evaluating &quot;Real World&quot; Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to investigate weekly prophylaxis dosing regimens used&#xD;
      in standard clinical practice.&#xD;
&#xD;
      In addition the study will capture reported bleed rate, pattern of change in KOVALTRY&#xD;
      prophylaxis dose &amp; dosing frequency, reason for choice of treatment regimen, FVIII product&#xD;
      switch pattern, patient treatment satisfaction and adherence, KOVALTRY pharmacokinetic data&#xD;
      (if performed), KOVALTRY consumption, as well as safety data.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label, prospective, non-interventional, single arm study in patients receiving KOVALTRY&#xD;
      as prophylaxis therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 14, 2016</start_date>
  <completion_date type="Actual">March 1, 2021</completion_date>
  <primary_completion_date type="Actual">December 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients on 2x and 3x weekly prophylaxis at end of observation period</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annualized composite number of reported bleeds (total, spontaneous, joint and trauma)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in predefined prophylaxis regimen per age group and per country</measure>
    <time_frame>At the end of observational period, up to 2 years</time_frame>
    <description>Age group: 0 to &lt;6, ≥6 to &lt;12, ≥12 to &lt;18, 18 and above&#xD;
Weekly prophylaxis dosing regimens:&#xD;
2 injections a week&#xD;
3 injections a week&#xD;
Injected on every other day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician decision determinants of prophylaxis regimen</measure>
    <time_frame>At baseline</time_frame>
    <description>Age i.v. access Current treatment regimen Bleeding history with current treatment regimen Prior history of life threatening bleed Number of target joints Pharmacokinetic data Adherence/Compliance history Activity level Patient/caregiver preference Caregiver support Insurance coverage (US) Institution guidelines Country guidelines Other</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to one year and two years in treatment satisfaction (Hemo-SAT)</measure>
    <time_frame>At baseline, 1 year and end of observational period, up to 2 years</time_frame>
    <description>Hemo-SAT - Hemophilia treatment satisfaction questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to six months, one year and two years in Validated Hemophilia Regimen Treatment Adherence Scale-Prophylaxis (VERITAS-PRO)</measure>
    <time_frame>At baseline, 6 months and end of observational period, up to 2 years</time_frame>
    <description>VERITAS - Validated Hemophilia Regimen Treatment Adherence Scale-Prophylaxis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of data relating to KOVALTRY PK</measure>
    <time_frame>At routine visits, up to 2 years</time_frame>
    <description>Pharmacokinectic (PK) parameters&#xD;
Area under the curve (AUC)&#xD;
Clearance (Cl)&#xD;
Half-life&#xD;
FVIII trough&#xD;
FVIII peak levels&#xD;
In-vivo recovery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The total annualized factor consumption (injections)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in prophylaxis dosing frequency (study start to end of observation period)</measure>
    <time_frame>At baseline and end of observation period, up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons for selection of initial dose / dosing frequency of Kovaltry (study start to end of observation period)</measure>
    <time_frame>At baseline and end of observation period, up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of KOVALTRY PK assessments performed</measure>
    <time_frame>At routine visits, up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">314</enrollment>
  <condition>Hemophilia A, Congenital</condition>
  <arm_group>
    <arm_group_label>BAY81-8973</arm_group_label>
    <description>Previously treated patients receiving IV infusion of KOVALTRY for routine prophylaxis</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973</intervention_name>
    <description>unmodified, full length recombinant FVIII</description>
    <arm_group_label>BAY81-8973</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Previously treated male patients with moderate to severe (≤ 5% FVIII:C) hemophilia A, with&#xD;
        ≥ 50 exposure days (EDs) to any FVIII product and with or without history of inhibitors who&#xD;
        have been prescribed KOVALTRY for a medically appropriate use will be eligible to be&#xD;
        included into this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male patients diagnosed with moderate to severe hemophilia A (≤ 5% FVIII:C (Factor&#xD;
             VIII Coagulant activity))&#xD;
&#xD;
          -  Any age&#xD;
&#xD;
          -  ≥ 50 exposure days (EDs) to any FVIII product&#xD;
&#xD;
          -  Patients with or without history of inhibitors&#xD;
&#xD;
               -  Patient with previous history of inhibitors, with at least 2 consecutive negative&#xD;
                  inhibitor tests and on standard prophylaxis therapy for at least 1 year prior to&#xD;
                  study entry&#xD;
&#xD;
               -  No current evidence of FVIII inhibitor or clinical suspicion of FVIII inhibitor&#xD;
&#xD;
                    -  Evidence of FVIII inhibitor as measured by the Nijmegen-modified Bethesda&#xD;
                       assay [&lt;0.6 Bethesda units (BU/mL)] or Bethesda assay [&lt; 1.0 BU/mL] in 2 on&#xD;
                       consecutives samples&#xD;
&#xD;
                    -  Documented or clinical suspicion of shortened FVIII half-life (&lt; 6 hrs)&#xD;
&#xD;
          -  Currently on or plan to start prophylaxis therapy with KOVALTRY&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients participating in an investigational program with interventions outside of&#xD;
             routine clinical practice&#xD;
&#xD;
          -  Patients with an additional diagnosis of any bleeding/coagulation disorder other than&#xD;
             hemophilia A&#xD;
&#xD;
          -  Patients on Immune Tolerance Induction (ITI) treatment at the time of enrollment&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Rehabilitation Services/ University of South Alabama</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hemophilia and Thrombosis Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Health Cancer Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic - Division of Pediatric Hematology/Oncology - Jacksonsville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic - Pensacola</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital Adult Hemophilia and Thrombosis Treatment Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University Center for Bleeding and Blood Clotting Disorders</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hemophilia Center of Western New York</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Carolina University - Brody School of Medicine</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital at OU Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Hemophilia &amp; Thrombosis Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Center for Bleeding Disorders / Blood Center of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Luxembourg</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Luxembourg</country>
    <country>Netherlands</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Slovakia</country>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 29, 2016</study_first_submitted>
  <study_first_submitted_qc>July 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2016</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Previously treated patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

